Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
| Autor: | Dirk Huebner, Emily K. Larsen, Scott E. Smith, Joseph D. Rosenblatt, Stephen M. Ansell, Joseph M. Connors, Ajay K. Gopal, Anas Younes, Kerry J. Savage, Robert T. Chen, Abraham P. Fong, Andreas Engert |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunoconjugates Immunology Salvage therapy Biochemistry Gastroenterology 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Refractory Internal medicine Refractory Hodgkin Lymphoma medicine Humans Brentuximab vedotin Survival rate Neoplasm Staging Brentuximab Vedotin Salvage Therapy business.industry Remission Induction Cell Biology Hematology Prognosis medicine.disease Hodgkin Disease Confidence interval Surgery Survival Rate Peripheral neuropathy 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local business 030215 immunology medicine.drug |
| Zdroj: | Blood. 128:1562-1566 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|